- Home
- NVS vs TMO Comparison
NVS vs TMO Comparison
Compare NVS & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVS
- TMO
- Stock Information
- Founded
- NVS 1895
- TMO 1956
- Country
- NVS Switzerland
- TMO United States
- Employees
- NVS N/A
- TMO N/A
- Industry
- NVS Biotechnology: Pharmaceutical Preparations
- TMO Industrial Machinery/Components
- Sector
- NVS Health Care
- TMO Industrials
- Exchange
- NVS Nasdaq
- TMO Nasdaq
- Market Cap
- NVS 230.5B
- TMO 203.5B
- IPO Year
- NVS 1991
- TMO N/A
- Fundamental
- Price
- NVS $110.18
- TMO $410.66
- Analyst Decision
- NVS Hold
- TMO Buy
- Analyst Count
- NVS 6
- TMO 19
- Target Price
- NVS $123.67
- TMO $603.84
- AVG Volume (30 Days)
- NVS 2.2M
- TMO 2.9M
- Earning Date
- NVS 04-29-2025
- TMO 04-23-2025
- Dividend Yield
- NVS 3.58%
- TMO 0.42%
- EPS Growth
- NVS N/A
- TMO 9.37
- EPS
- NVS 6.38
- TMO 17.06
- Revenue
- NVS $53,222,000,000.00
- TMO $42,898,000,000.00
- Revenue This Year
- NVS $5.88
- TMO $3.25
- Revenue Next Year
- NVS $2.07
- TMO $6.54
- P/E Ratio
- NVS $17.51
- TMO $24.09
- Revenue Growth
- NVS 11.50
- TMO 0.95
- 52 Week Low
- NVS $96.06
- TMO $402.81
- 52 Week High
- NVS $120.92
- TMO $627.88
- Technical
- Relative Strength Index (RSI)
- NVS 48.41
- TMO 34.48
- Support Level
- NVS $110.54
- TMO $415.38
- Resistance Level
- NVS $114.88
- TMO $431.44
- Average True Range (ATR)
- NVS 1.52
- TMO 12.81
- MACD
- NVS -0.10
- TMO 1.16
- Stochastic Oscillator
- NVS 12.48
- TMO 13.35
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
About TMO Thermo Fisher Scientific Inc
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).